In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Claire Aldridge, Chief Strategy Officer at Form Bio.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Claire, covering:
Claire Aldridge, Ph.D. is Chief Strategy Officer for Form Bio, the first spinout from the de-extinction and biodiversity company, Colossal Biosciences. Prior to this role, she was Senior Vice President, Chief of Staff and Corporate Strategy at Taysha Gene Therapies, a Dallas based company focusing on eradicating monogenic CNS disease. She previously served as Associate Vice President for Commercialization and Business Development at UT Southwestern Medical Center and VP, Venture Development with Remeditex Ventures, a local biotech venture fund.
Dr. Aldridge brings more than 20 years’ experience facilitating the translation of scientific discoveries into patient and commercial benefits. Dr. Aldridge is also on the Scientific Advisory Board for Colossal Biosciences, the Board of Directors for MedCognetics and 4E Therapeutics and is the chair for the Industry Advisory Council for the UT Dallas Department of Biomedical Engineering. Dr. Aldridge received her Ph.D. from Duke University in the Department of Immunology and Program in Genetics, and her Bachelor of Science in Biomedical Science is from Texas A&M University.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.